KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) Research & Development (2016 - 2025)

Johnson & Johnson (JNJ) has disclosed Research & Development for 17 consecutive years, with -$10.3 billion as the latest value for Q4 2025.

  • Quarterly Research & Development fell 2.09% to -$10.3 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $109.0 million through Dec 2025, down 94.08% year-over-year, with the annual reading at $109.0 million for FY2025, 94.08% down from the prior year.
  • Research & Development hit -$10.3 billion in Q4 2025 for Johnson & Johnson, down from $3.7 billion in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.0 billion in Q3 2024 to a low of -$10.3 billion in Q4 2025.
  • Historically, Research & Development has averaged $2.3 billion across 5 years, with a median of $3.5 billion in 2022.
  • Biggest YoY gain for Research & Development was 43.66% in 2024; the steepest drop was 325.29% in 2024.
  • Year by year, Research & Development stood at $3.4 billion in 2021, then rose by 1.84% to $3.5 billion in 2022, then increased by 28.55% to $4.5 billion in 2023, then tumbled by 325.29% to -$10.1 billion in 2024, then dropped by 2.09% to -$10.3 billion in 2025.
  • Business Quant data shows Research & Development for JNJ at -$10.3 billion in Q4 2025, $3.7 billion in Q3 2025, and $3.5 billion in Q2 2025.